Pharma & Biotech Global Week in Review 6 January 2010 from IP Think Tank

Here is IP Think Tank’s weekly selection of top Pharma & Biotech intellectual property news breaking in the blogosphere and internet.

Please join the discussion by adding your comments on any of these stories, and please do let us know if you think we’ve missed something important, or if there is a source you think should be monitored.

You can separately subscribe to the IP Think Tank Global Week in Review at the Subscribe page: http://thinkipstrategy.com/subscribe/

 
Highlights this week included:

Wellbutrin (Bupropion) – US: An employee benefit plan files motion to certify class action against Biovail and GlaxoSmithKline alleging companies conspired to delay generic Wellbutrin by filing baseless patent suits (GenericsWeb)

Emend (Fosaprepitant dimeglumine) – US: FDA issues exclusivity decision for Merck’s Emend; Agency reverses course and grants NCE exclusivity (FDA Law Blog)

Strattera (Atomoxetine) – US: District Court New Jersey finds Teva, Actavis, Mylan, Sun, Sandoz, Apotex and Aurobindo induced infringement of Eli Lilly’s Strattera patent (Patent Docs)

 
General

Patent protection – an eternal topic of R&D-oriented drug companies (China IP)

Fair comments on ‘fake drugs’? – Response to IP Watch article ‘Fake scare about fake drugs’ (Spicy IP)

Patents and crop diversity (Patently-O)

Top Stories of 2009 (Patent Docs) (Patent Docs) (Patent Docs)

SPC resources (SPC Blog)

EU: Paediatric exclusivities: a new article – ‘Paediatric exclusivities in Europe – a quest for the holy grail?’ (The SPC Blog)

India: Reviewing the Indian Patent Regime after 5 years of the introduction of the pharmaceutical product patent regime (Spicy IP)

UK: Department of Health proposing generic prescription drugs option (GenericsWeb)

US: 7th Circuit: Enforcing contracts between joint owners: Wisconsin Alumni Research Foundation (WARF) v. Xenon Pharma (Patently-O)

US: Universities well positioned as pharma companies scramble to refill pipelines (Technology Transfer Tactics)

US: Paratek Pharaceuticals seeks review and correction of patent term adjustment calculation for patent covering ‘9-Aminomethyl Substituted Minocycline Compounds’ (Patent Docs)

US: Tulane University seeks correction of inventorship for patents covering peptide analogs of the human glucagon-like peptide hormone: Administrators of the Tulane Educational Fund et al. v. Ipsen Pharma, S.A.S. et al. (Patent Docs)

 
Products

Angiomax (Bivalirudin) – US: Medicines Company files patent infringement complaints against Pliva Hrvatska and Teva following Para IV challenge (Patent Docs) (Patent Docs) (IP Factor)

Emend (Fosaprepitant dimeglumine) – US: FDA issues exclusivity decision for Merck’s Emend; Agency reverses course and grants NCE exclusivity (FDA Law Blog)

Gemzar (Gemcitabine) – US: Eli Lilly in new patent fight for chemotherapy drug (GenericsWeb)

Humira (Adalimumab) – US: As Abbott appeals, Centocor seeks continuing damages in Humira dispute (Patent Docs)

Meridia (Sibutramine) – US: Abbot files patent infringement suit against Apotex following Para IV challenge (Patent Docs)

Solodyn (Minocycline) – US: Medicis files patent infringement complaint against Barr Laboratories and Teva following Para IV challenge (Patent Docs)

Strattera (Atomoxetine) – US: District Court New Jersey finds Teva, Actavis, Mylan, Sun, Sandoz, Apotex and Aurobindo induced infringement of Eli Lilly’s Strattera patent (Patent Docs)

Viagra (Sildenafil) – Austria: Supreme Court (Oberste Gerichtshof) finds ‘Styriagra’ branded organic blue pills take unfair advantage of Pfizer’s Viagra trade mark (IPKat) (Austrotrabant’s Blog)

Viagra (Sildenafil) – Israel Court issues stiff sentence to fake Viagra distributors (IP Factor)

Wellbutrin (Bupropion) – US: An employee benefit plan files motion to certify class action against Biovail and GlaxoSmithKline alleging companies conspired to delay generic Wellbutrin by filing baseless patent suits (GenericsWeb)

Zyprexa (Olanzapine) – UK: Dr Reddy’s challenge to Eli Lilly’s Olanzapine patent fails (Spicy IP)

 

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

%d bloggers like this: